Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: DDX3X

Summary for DDX3X

Gene information	Gene symbol	DDX3X
	Ensembl ID	ENSG00000215301
	Entrez ID	1654
	Gene name	DEAD-box helicase 3 X-linked
	Synonyms	CAP-Rf\|DBX\|DDX14\|DDX3\|HLP2
	Gene type	protein_coding
	UniProtAcc	O00571

Top

Dataset with differentially expressed gene: DDX3X

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-0.552411	2.97e-05
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.468543	3.09e-40
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.465942	4.96e-13
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.506581	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.369105	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.331388	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.393693	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.497635	4.12e-13
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.335461	6.15e-20
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.576796	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.409111	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.435375	4.40e-20
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.416436	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.422741	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.276304	1.40e-16
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.256884	2.17e-07
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.743966	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.667911	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.346155	2.19e-16
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.361876	3.18e-04
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.551165	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.253256	3.46e-43
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.37799	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.501999	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.489612	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.260971	1.97e-04
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.273979	1.87e-06
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.40886	3.79e-23
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.250901	0.00e+00

Top

Expression of DDX3X in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to DDX3X

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating DDX3X

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
DDX3X	hsa-miR-641	84.6871	NM_001193416
DDX3X	hsa-miR-137-3p	84.5469	NM_001193416
DDX3X	hsa-miR-670-5p	84.3513	NM_001193416
DDX3X	hsa-miR-4264	83.9996	NM_001193416
DDX3X	hsa-miR-510-3p	83.9077	NM_001193416
DDX3X	hsa-miR-1266-3p	83.5696	NM_001193416
DDX3X	hsa-miR-4666a-5p	83.3757	NM_001193416
DDX3X	hsa-miR-587	83.3221	NM_001193416
DDX3X	hsa-miR-339-5p	83.2091	NM_001193416
DDX3X	hsa-miR-146b-3p	83.0612	NM_001193416
DDX3X	hsa-miR-4731-3p	83.0064	NM_001193416
DDX3X	hsa-miR-2276-3p	82.9398	NM_001193416
DDX3X	hsa-miR-101-3p	82.8186	NM_001193416
DDX3X	hsa-miR-506-3p	82.7554	NM_001193416
DDX3X	hsa-miR-124-3p	82.7554	NM_001193416
DDX3X	hsa-miR-6513-3p	82.2133	NM_001193416
DDX3X	hsa-miR-548av-3p	81.7423	NM_001193416
DDX3X	hsa-miR-7161-5p	81.4734	NM_001193416
DDX3X	hsa-miR-6808-3p	81.4422	NM_001193416
DDX3X	hsa-miR-4480	81.2797	NM_001193416
DDX3X	hsa-miR-2278	80.3336	NM_001193416
DDX3X	hsa-miR-4531	80.1357	NM_001193416
DDX3X	hsa-miR-548u	80.1101	NM_001193416
DDX3X	hsa-miR-6875-3p	80.0447	NM_001193416

Page: 1 2 3

Top

Motifs and transcription factors (TFs) regulating DDX3X

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
DDX3X	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
DDX3X	transfac_pro__M04950	EGR1 (directAnnotation).
DDX3X	taipale_cyt_meth__E2F2_GCGCGCGCGYW_eDBD_repr	E2F2 (directAnnotation).
DDX3X	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
DDX3X	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
DDX3X	transfac_pro__M00652	NRF1 (directAnnotation).
DDX3X	hdpi__ETV4	ETV4 (directAnnotation).
DDX3X	transfac_pro__M04866	HDAC2 (directAnnotation).
DDX3X	swissregulon__hs__ZBTB14	ZBTB14 (directAnnotation).
DDX3X	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
DDX3X	metacluster_141.6	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).
DDX3X	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
DDX3X	metacluster_141.4	GLIS2 (directAnnotation).
DDX3X	jaspar__MA0748.2	YY2 (directAnnotation).
DDX3X	dbtfbs__GMEB2_HepG2_ENCSR745VSQ_merged_N1	GMEB2 (directAnnotation).
DDX3X	hdpi__TP73	TP73 (directAnnotation).
DDX3X	flyfactorsurvey__pho_SOLEXA_F1-3	YY1 (inferredBy_Orthology).
DDX3X	metacluster_33.8	BRCA1; CHD2; CHD2; ETS1; NR3C1; ZBED1; ZBED1; ZBED1; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33 (directAnnotation). CHD2; ZBTB33 (inferredBy_Orthology).
DDX3X	transfac_pro__M06259	ZNF91 (directAnnotation).
DDX3X	stark__RCGCMATTW	YY1 (inferredBy_Orthology).
DDX3X	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_repr	ZNF385D (directAnnotation).
DDX3X	metacluster_174.3	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).
DDX3X	transfac_pro__M05893	ZNF676 (directAnnotation).
DDX3X	metacluster_198.7	AHR; ZBTB14; ZBTB14; ZBTB14 (directAnnotation).
DDX3X	swissregulon__mm__E2f7	E2F7 (inferredBy_Orthology).
DDX3X	metacluster_135.11	NR2C2 (directAnnotation).
DDX3X	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
DDX3X	metacluster_198.3	ZFP64 (directAnnotation).
DDX3X	metacluster_141.5	NR3C1; THAP1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZNF597 (directAnnotation). YY1; YY1; YY1; YY2; ZFP42 (inferredBy_Orthology).
DDX3X	hdpi__ZNF304	ZNF304 (directAnnotation).
DDX3X	metacluster_151.2	ZNF23 (directAnnotation).
DDX3X	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
DDX3X	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
DDX3X	taipale_tf_pairs__TFAP2C_E2F8_NNTCCCGCNNNCCNNNGGC_CAP_repr	E2F8; TFAP2C (directAnnotation).
DDX3X	jaspar__MA1721.1	ZNF93 (directAnnotation).
DDX3X	tfdimers__MD00364	WT1 (directAnnotation).
DDX3X	metacluster_23.9	GLIS1; GLIS3; GLIS3; ZNF575 (directAnnotation). GLIS2; GLIS2; GLIS3; ZNF575; ZXDA; ZXDA; ZXDA; ZXDA; ZXDB; ZXDB; ZXDB; ZXDB; ZXDC; ZXDC; ZXDC; ZXDC (inferredBy_Orthology).
DDX3X	metacluster_143.13	ZBTB7A (directAnnotation).
DDX3X	kznf__ZNF2_Imbeault2017_OM_RCADE	ZNF2 (directAnnotation).
DDX3X	hdpi__ELF2	ELF2 (directAnnotation).
DDX3X	metacluster_2.9	IRF2; IRF2; IRF2; PRDM1; PRDM1 (directAnnotation). PRDM1 (inferredBy_Orthology).
DDX3X	transfac_pro__M05650	ZNF44 (directAnnotation).
DDX3X	tfdimers__MD00527	IRF1; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF8; ZEB1 (directAnnotation).
DDX3X	tfdimers__MD00007	E2F1; IRF8 (directAnnotation).
DDX3X	metacluster_166.4	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).
DDX3X	transfac_pro__M04826	EP300 (directAnnotation).
DDX3X	jaspar__MA1708.1	ETV7 (directAnnotation).
DDX3X	metacluster_183.4	ETS1 (inferredBy_Orthology).
DDX3X	taipale_tf_pairs__FOXO1_ELK1_RSCGGATGTTRTN_CAP	ELK1; FOXO1 (directAnnotation).
DDX3X	metacluster_81.7	CREB1 (directAnnotation).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."